Combination therapy for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have stage III or IV squamous non-small cell lung cancer that cannot be treated with surgery or radiation to cure it.
- Your tumor must be PD-L1 positive (TPS ≥ 1%) — this means your cancer cells have a certain protein that the study drug targets.
- You cannot have had any prior treatment for advanced lung cancer, including chemotherapy, targeted therapy, or immunotherapy.
- You must be in good general health (able to perform daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial compares a new combination of drugs (one that targets cancer cells and another that boosts the immune system) against a standard chemotherapy plus immune therapy combination. The goal is to see if the new approach works better as a first treatment for advanced squamous lung cancer.
This trial tests a new combination of drugs (HLX07, serplulimab, and chemotherapy) for people with advanced squamous non-small cell lung cancer that hasn't been treated before. The goal is to see if this combo works better than the current standard treatments.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.